1
|
Naveiras O, Schyrr F, Campos V, Alonso-Calleja A, Weid BVD, Reiner P, Gardeux V, Sarkis R, Oggier A, Lopes S, Banfi D, Kuttler F, Deplancke B, Turcatti G. 2013 – A LABEL-FREE, HIGH-THROUGHPUT PHENOTYPIC SCREEN OF ADIPOCYTIC DIFFERENTIATION MODULATORS TO ACCELERATE HEMATOPOIETIC RECOVERY. Exp Hematol 2022. [DOI: 10.1016/j.exphem.2022.07.045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
2
|
Lucas S, Tencerova M, von der Weid B, Andersen TL, Attané C, Behler-Janbeck F, Cawthorn WP, Ivaska KK, Naveiras O, Podgorski I, Reagan MR, van der Eerden BCJ. Guidelines for Biobanking of Bone Marrow Adipose Tissue and Related Cell Types: Report of the Biobanking Working Group of the International Bone Marrow Adiposity Society. Front Endocrinol (Lausanne) 2021; 12:744527. [PMID: 34646237 PMCID: PMC8503265 DOI: 10.3389/fendo.2021.744527] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/20/2021] [Accepted: 08/24/2021] [Indexed: 12/19/2022] Open
Abstract
Over the last two decades, increased interest of scientists to study bone marrow adiposity (BMA) in relation to bone and adipose tissue physiology has expanded the number of publications using different sources of bone marrow adipose tissue (BMAT). However, each source of BMAT has its limitations in the number of downstream analyses for which it can be used. Based on this increased scientific demand, the International Bone Marrow Adiposity Society (BMAS) established a Biobanking Working Group to identify the challenges of biobanking for human BMA-related samples and to develop guidelines to advance establishment of biobanks for BMA research. BMA is a young, growing field with increased interest among many diverse scientific communities. These bring new perspectives and important biological questions on how to improve and build an international community with biobank databases that can be used and shared all over the world. However, to create internationally accessible biobanks, several practical and legislative issues must be addressed to create a general ethical protocol used in all institutes, to allow for exchange of biological material internationally. In this position paper, the BMAS Biobanking Working Group describes similarities and differences of patient information (PIF) and consent forms from different institutes and addresses a possibility to create uniform documents for BMA biobanking purposes. Further, based on discussion among Working Group members, we report an overview of the current isolation protocols for human bone marrow adipocytes (BMAds) and bone marrow stromal cells (BMSCs, formerly mesenchymal), highlighting the specific points crucial for effective isolation. Although we remain far from a unified BMAd isolation protocol and PIF, we have summarized all of these important aspects, which are needed to build a BMA biobank. In conclusion, we believe that harmonizing isolation protocols and PIF globally will help to build international collaborations and improve the quality and interpretation of BMA research outcomes.
Collapse
Affiliation(s)
- Stephanie Lucas
- Marrow Adiposity and Bone Lab-MABLab ULR4490, Univ. Littoral Côte d’Opale, Boulogne-sur-Mer, Univ. Lille, CHU Lille, Lille, France
| | - Michaela Tencerova
- Molecular Physiology of Bone, Institute of Physiology of the Czech Academy of Sciences, Prague, Czechia
| | - Benoit von der Weid
- School of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
- Swiss Institute of Bioinformatics, Lausanne, Switzerland
- Department of Biomedical Sciences, Faculty of Biology and Medicine, Université de Lausanne, Lausanne, Switzerland
| | - Thomas Levin Andersen
- Clinical Cell Biology, Department of Pathology, Odense University Hospital, Odense, Denmark
- Clinical Cell Biology, Pathology Research Unit, Department of Clinical Research, University of Southern Denmark, Odense, Denmark
- Department of Molecular Medicine, University of Southern Denmark, Odense, Denmark
- Department of Forensic Medicine, Aarhus University, Aarhus, Denmark
| | - Camille Attané
- Institute of Pharmacology and Structural Biology, Université de Toulouse, CNRS UMR 5089, Toulouse, France
- Equipe labellisée Ligue contre le cancer, Toulouse, France
| | - Friederike Behler-Janbeck
- Department of Biochemistry and Molecular Cell Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- Department of Orthopedics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - William P. Cawthorn
- British Heart Foundation Centre for Cardiovascular Science, The Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom
| | - Kaisa K. Ivaska
- Institute of Biomedicine, University of Turku, Turku, Finland
| | - Olaia Naveiras
- Department of Biomedical Sciences, Faculty of Biology and Medicine, Université de Lausanne, Lausanne, Switzerland
- Hematology Service, Departments of Oncology and Laboratory Medicine, Lausanne University Hospital (CHUV), Université de Lausanne, Lausanne, Switzerland
| | - Izabela Podgorski
- Department of Pharmacology, Wayne State University School of Medicine and Karmanos Cancer Institute, Detroit, MI, United States
| | - Michaela R. Reagan
- Center for Molecular Medicine, Maine Medical Center Research Institute, Scarborough, ME, United States
- Graduate School for Biomedical Science, Tufts University, Boston, MA, United States
| | - Bram C. J. van der Eerden
- Laboratory for Calcium and Bone Metabolism, Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, Netherlands
- *Correspondence: Bram C. J. van der Eerden,
| |
Collapse
|
3
|
Hatterer E, Barba L, Noraz N, Daubeuf B, Aubry-Lachainaye JP, von der Weid B, Richard F, Kosco-Vilbois M, Ferlin W, Shang L, Buatois V. Co-engaging CD47 and CD19 with a bispecific antibody abrogates B-cell receptor/CD19 association leading to impaired B-cell proliferation. MAbs 2019; 11:322-334. [PMID: 30569825 PMCID: PMC6380423 DOI: 10.1080/19420862.2018.1558698] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
CD19 is a B cell-specific receptor that regulates the threshold of B cell receptor (BCR)-mediated cell proliferation. A CD47xCD19 bispecific antibody (biAb) was generated to target and deplete B cells via multiple antibody-mediated mechanisms. Interestingly, the biAb, constructed of a CD19 binding arm and a CD47 binding arm, inhibited BCR-mediated B-cell proliferation with an effect even more potent than a CD19 monoclonal antibody (mAb). The inhibitory effect of the biAb was not attributable to CD47 binding because a monovalent or bivalent anti-CD47 mAb had no effect on B cell proliferation. Fluorescence resonance energy transfer analysis demonstrated that co-engaging CD19 and CD47 prevented CD19 clustering and its migration to BCR clusters, while only engaging CD19 (with a mAb) showed no impact on either CD19 clustering or migration. The lack of association between CD19 and the BCR resulted in decreased phosphorylation of CD19 upon BCR activation. Furthermore, the biAb differentially modulated BCR-induced gene expression compared to a CD19 mAb. Taken together, this unexpected role of CD47xCD19 co-ligation in inhibiting B cell proliferation illuminates a novel approach in which two B cell surface molecules can be tethered, to one another in order, which may provide a therapeutic benefit in settings of autoimmunity and B cell malignancies.
Collapse
Affiliation(s)
- Eric Hatterer
- a Exploratory Sciences , NovImmune SA , Plan les Ouates , Switzerland
| | - Leticia Barba
- a Exploratory Sciences , NovImmune SA , Plan les Ouates , Switzerland
| | - Nelly Noraz
- b INSERM U1217, Institut NeuroMyoGène, Lyon , University Claude Bernard Lyon 1 , Lyon , France
| | - Bruno Daubeuf
- a Exploratory Sciences , NovImmune SA , Plan les Ouates , Switzerland
| | | | | | - Françoise Richard
- a Exploratory Sciences , NovImmune SA , Plan les Ouates , Switzerland
| | | | - Walter Ferlin
- a Exploratory Sciences , NovImmune SA , Plan les Ouates , Switzerland
| | - Limin Shang
- a Exploratory Sciences , NovImmune SA , Plan les Ouates , Switzerland
| | - Vanessa Buatois
- a Exploratory Sciences , NovImmune SA , Plan les Ouates , Switzerland
| |
Collapse
|